文献速递甲状腺疾病

乐伐替尼治疗甲状腺癌的3期研究中肿瘤大小随时间变化的特征分析

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2016-08-22

基于SELECT 3期随机双盲多中心研究,探索性分析乐伐替尼(n=261)与安慰剂(n=131)治疗放射性碘难治性分化型甲状腺癌的肿瘤大小变化。乐伐替尼组肿瘤最大径中位最大变化为-42.9%,缩小在首次评估(第8周)最明显(中位-24.7%),此后速率减慢但持续(每月-1.3%)。首次评估时肿瘤大小变化百分比对无进展生存期的预测呈边缘显著(P=.06)。

要点

  • 乐伐替尼组肿瘤最大径中位最大变化-42.9%,其中应答者-51.9%,非应答者-20.2%。
  • 肿瘤缩小在随机后8周首次评估最明显(中位-24.7%),之后每月-1.3%持续缩小。
  • 首次评估时肿瘤大小变化百分比对无进展生存期的预测呈边缘显著(P=.06)。

关键数值与推荐

  • 肿瘤评估由独立影像学审查按实体瘤疗效评价标准1.1版每8周进行。
  • 乐伐替尼24 mg每日一次,28天为一周期,直至不可接受的毒性、疾病进展或死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Lenvatinib improved the progression-free survival (PFS) and overall response rate of patients with radioiodine-refractory differentiated thyroid cancer vs placebo in the Phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT). OBJECTIVE: The objective of the study was to characterize tumor size changes with lenvatinib treatment. DESIGN: SELECT was a phase 3, randomized, double-blind, multicenter study. SETTING: In this clinical trial, tumor assessments of lenvatinib (n = 261) and placebo-treated (n = 131) patients were performed by independent radiological review per Response Evaluation Criteria in Solid Tumors version, 1.1 at 8-week intervals. PATIENTS: Patients with complete or partial response were defined as responders to lenvatinib (n = 169). Of the 92 nonresponders, 76 had at least one postbaseline tumor assessment and were included in this analysis. INTERVENTIONS: Lenvatinib (24 mg once daily) or placebo in 28-day cycles until unacceptable toxicity, disease progression, or death. MAIN OUTCOME MEASURES: This was an exploratory analysis of key end points from SELECT, including PFS, overall response rate, and tumor reduction. RESULTS: The median maximum percentage change in tumor size was -42.9% for patients receiving lenvatinib (responders, -51.9%; nonresponders, -20.2%). Tumor size reduction was most pronounced at first assessment (median, -24.7% at 8 wk after randomization); thereafter, the rate of change was slower but continuous (-1.3% per mo). In a multivariate model, percentage change in tumor size at the first assessment was a marginally significant positive predictor for PFS (P = .06). CONCLUSIONS: The change in tumor size conferred by lenvatinib was characterized by two phases: an initial, rapid decline, followed by slower, continuous shrinkage.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Robinson B, Schlumberger M, Wirth LJ, et al. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab. 2016. PMID: 27548104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。